ArticleNPJ systems biology and applications2026
Optimal control theory as a method for designing multidrug adaptive therapy regimens.
Article in NPJ systems biology and applications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evolutionarily informed regimens offer new approaches that hope to combat the development of resistance during cancer treatment. These regimens are often complicated to design. In this work, we use optimal control theory (OCT) to guide the design of a two-drug adaptive therapy regimen. We begin with a logistic differential equation model of a tumor composed of four populations with different resistance to two drugs. OCT analysis identified rules regarding regimen creation. We simulated various regimen designs, and we found that regimens prioritizing maintenance of competition between resistant and sensitive populations performed the best. Results were robust across parameters, indicating that the ability to maintain competition was more important than the technique used. With regimens identified, we compared them to practical and standard-of-care regimens to predict future in vitro performance. Practical regimens still outperform standard-of-care for nearly all parameters. As such, OCT offers one avenue for exploring multidrug adaptive regimen design.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.